Carrier-Mediated Delivery of Low-Molecular-Weight <i>N</i>-Containing Drugs across the Blood-Brain Barrier or the Blood-Retinal Barrier Using the Proton-Coupled Organic Cation Antiporter
While it is true that pharmacotherapy has achieved desired health outcomes, significant unmet medical needs persist in the field of central nervous system (CNS) drugs, particularly for neurodegenerative diseases such as Alzheimer's disease, as well as ocular diseases such as diabetic retinopath...
Saved in:
Main Author: | Toshihiko Tashima (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Substance Delivery across the Blood-Brain Barrier or the Blood-Retinal Barrier Using Organic Cation Transporter Novel Type 2 (OCTN2)
by: Toshihiko Tashima
Published: (2024) -
Proteomics-Based Transporter Identification by the PICK Method: Involvement of TM7SF3 and LHFPL6 in Proton-Coupled Organic Cation Antiport at the Blood-Brain Barrier
by: Toshiki Kurosawa, et al.
Published: (2022) -
Mesenchymal Stem Cell (MSC)-Based Drug Delivery into the Brain across the Blood-Brain Barrier
by: Toshihiko Tashima
Published: (2024) -
Non-Invasive Device-Mediated Drug Delivery to the Brain across the Blood-Brain Barrier
by: Toshihiko Tashima, et al.
Published: (2024) -
Comprehensive Evidence of Carrier-Mediated Distribution of Amantadine to the Retina across the Blood-Retinal Barrier in Rats
by: Yusuke Shinozaki, et al.
Published: (2021)